Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections; glycine - replacement therapy in: - primary immunodeficiency (pi) diseases; - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation in: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count; - guillain barr? syndrome (gbs); - chronic inflammatory demyelinating polyneuropathy (cidp); - kawasaki disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 mg/ml - injection - excipient ingredients: glycine; water for injections - replacement therapy in: - primary immunodeficiency (pi) diseases; - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation in: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count; - guillain barr? syndrome (gbs); - chronic inflammatory demyelinating polyneuropathy (cidp); - kawasaki disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections; glycine - replacement therapy in: - primary immunodeficiency (pi) diseases; - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation in: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count; - guillain barr? syndrome (gbs); - chronic inflammatory demyelinating polyneuropathy (cidp); - kawasaki disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 mg/ml - injection - excipient ingredients: glycine; water for injections - replacement therapy in: - primary immunodeficiency (pi) diseases; - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation in: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count; - guillain barr? syndrome (gbs); - chronic inflammatory demyelinating polyneuropathy (cidp); - kawasaki disease.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 0.24 mg/g (equivalent: betamethasone, qty 0.2 mg/g) - cream - excipient ingredients: cetomacrogol 1000; cetostearyl alcohol; white soft paraffin; liquid paraffin; purified water; chlorocresol; monobasic sodium phosphate; phosphoric acid; sodium hydroxide - indications as at 23 april 2004 : eczema includiing: atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - clobetasone butyrate - cream - clobetasone butyrate 0.05 %w/w - clobetasone - clobetasone - eumovate cream is a moderately potent topical corticosteroid indicated for adults, elderly, children and infants for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.these include the following:- atopic dermatitis- irritant or allergic contact dermatitis- seborrhoeic dermatitis- nappy rash- photodermatitis- otitis externa- prurigo nodularis- insect bite reactionseumovate may be used as maintenance therapy between courses of one of the more potent topical steroids.

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tretinoin, quantity: 0.5 mg/g - cream - excipient ingredients: propylene glycol; purified water; peg-40 stearate; white soft paraffin; propyl hydroxybenzoate; disodium edetate; stearyl alcohol; stearic acid; methyl hydroxybenzoate; butylated hydroxytoluene; isopropyl palmitate; butylated hydroxyanisole - indicated for use in the treatment of acne vulgaris, in particular forms where comedones, papules and pustules predominate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tretinoin, quantity: 0.25 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; propylene glycol; propyl hydroxybenzoate; white soft paraffin; purified water; stearic acid; peg-40 stearate; butylated hydroxyanisole; butylated hydroxytoluene; stearyl alcohol; isopropyl palmitate; disodium edetate - indicated for use in the treatment of acne vulgaris, in particular forms where comedones, papules and pustules predominate.

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - betamethasone as valerate - cream - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.